BioCentury | Jul 10, 2018
Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum...
BioCentury | May 1, 2018
Distillery Therapeutics

Cancer

...Kalaany, Harvard Medical School, Boston, Mass. email: nada.kalaany@childrens.harvard.edu Elizabeth S. Eaton Harvard Medical School Insulin receptor substrate 1 (IRS1) Insulin receptor substrate 2 (IRS2) K-Ras...
BioCentury | Jan 20, 2017
Company News

TyrNovo, Kitov deal

Kitov acquired 56% of TyrNovo for $2 million in cash and $1.8 million in stock. TyrNovo’s NT219 , a small molecule inhibitor of insulin receptor substrate 1 (IRS1) , IRS2 and signal transducer and activator of transcription...
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Insulin receptor substrate 1 (IRS1); K-Ras (KRAS); Janus kinase-1 (JAK-1); JAK-2

Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest JAK inhibitors could help treat KRAS-mutant lung cancers. In patients with KRAS-mutant lung adenocarcinoma, low primary tumor levels of IRS1 were associated with...
BioCentury | Nov 13, 2014
Distillery Techniques

Technology: Drug platforms

...cells expressing TCRs that engage with phosphopeptide antigens could help treat various cancers. Levels of insulin receptor substrate 2 (IRS2)...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BioCentury | May 19, 2014
Clinical News

Aganirsen: Phase III data

Data from 69 patients with keratitis-related progressive corneal neovascularization in the intent-to-treat (ITT) population of the double-blind, European Phase III I-CAN trial showed that twice-daily 86 µg aganirsen eye drops per eye missed the primary...
BioCentury | May 13, 2014
Clinical News

Gene Signal publishes mixed data for aganirsen

Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101 ) eye drops from Gene Signal International S.A. (Lausanne, Switzerland) missed the primary endpoint of improving absolute mean visual acuity value from baseline to day 90 vs....
BioCentury | Apr 28, 2014
Clinical News

Aganirsen: Phase IIa data

A double-blind Phase IIa trial in 12 patients with psoriasis showed that once-daily 0.86 and 1.72 mg/g topical aganirsen each met the primary endpoint of reducing psoriatic lesion size from baseline to week 6 vs....
BioCentury | May 23, 2013
Cover Story

IRS audit for tumors

An Israeli academic-industry partnership has discovered small molecules that interfere wi th signaling by insulin-like growth factor-1 receptor , a cancer-associated receptor tyrosine kinase . The new compounds, licensed to NovoTyr Therapeutics Ltd. , could be superior to...
Items per page:
1 - 10 of 23